Develops biopharmaceuticals for cancer and autoimmune diseases, focusing on novel drug delivery technologies and immune modulation.
Nektar Therapeutics is a prominent biopharmaceutical company at the forefront of discovering and developing medicines to address critical unmet medical needs globally. Headquartered in San Francisco, California, the company is dedicated to advancing innovative therapies across a broad spectrum of therapeutic areas.
Among its leading products, Bempegaldesleukin stands out as a CD122-preferential interleukin-2 (IL-2) pathway agonist currently undergoing extensive clinical trials. These trials include Phase 3 studies targeting metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma. Additionally, Nektar Therapeutics is actively developing NKTR-358, a cytokine Treg stimulant in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and NKTR-255, an IL-15 receptor agonist progressing through Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer.
Founded in 1990, Nektar Therapeutics has established strategic collaborations with leading pharmaceutical entities such as Takeda Pharmaceutical Company Ltd., AstraZeneca AB, Roche, Pfizer Inc., Amgen Inc., and Bristol-Myers Squibb Company. These partnerships amplify its research and development efforts, bolstering its mission to pioneer transformative therapies that improve patient outcomes worldwide.